金黄色葡萄球菌菌血症的不同临床终点使结局评估复杂化
该回顾性观察研究纳入2019年12月20日至2022年8月23日期间464例成人金黄色葡萄球菌菌血症(SAB)患者,比较宿主、临床和微生物学特征。研究发现SAB存在不同临床终点:早期死亡与多病共存和年龄相关;转移性感染(以肌肉骨骼为主)与社区获得、持续发热、持续菌血症和复发相关;心内膜炎与老年多病共存患者的晚期死亡相关。
要点
- SAB患者经历不同临床终点:早期死亡、转移性感染、心内膜炎和无并发症菌血症。
- 归因死亡与Charlson共病指数和年龄强相关,但与转移性感染无关。
- 心内膜炎不同于其他转移性并发症,与死亡率增加相关。
核心结论
- SAB患者存在不同临床终点:早期死亡与多病共存和年龄相关;转移性感染以肌肉骨骼为主;心内膜炎与老年多病共存患者的晚期死亡相关;以及无并发症菌血症。
- 这些区别对临床试验选择合适结局可能重要:减少死亡率与改善转移性SAB患者临床反应可能需要不同干预措施。
研究设计与样本
- 回顾性观察研究,纳入2019年12月20日至2022年8月23日期间464例成人SAB患者。
- 使用简单逻辑回归、比值比和z评分比较宿主、临床和微生物学特征。
主要发现
- 归因死亡与转移性感染共同出现不频繁。
- Charlson共病指数和年龄与归因死亡强相关,但与转移性感染不相关。
- fatal SAB(无临床明显转移性并发症)占队列14.4%,转移性SAB(无归因死亡)占22.2%,无并发症占56.7%,重叠致命/转移性SAB占6.7%。
- 与无并发症SAB相比,致命性SAB特异与年龄较大和多病共存相关。
- 转移性SAB特异与社区获得、持续发热、持续菌血症和复发相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to test the hypothesis that development of metastatic infection represents a distinct clinical endpoint from death due to Staphylococcus aureus bacteremia (SAB). METHODS: We conducted a retrospective observational study of adults with SAB between 20 December 2019 and 23 August st2022 (n = 464). Simple logistic regression, odds ratios, and z-scores were used to compare host, clinical, and microbiologic features. RESULTS: Co-occurrence of attributable mortality and metastatic infection was infrequent. Charlson Comorbidity Index and age were strongly associated with attributable mortality, but not metastatic infection. We compared patients with fatal SAB (without clinically-apparent metastatic complications, 14.4% of cohort), metastatic SAB (without attributable mortality, 22.2%), neither complication (56.7%), and overlapping fatal/metastatic SAB (6.7%). Compared to SAB without complications, fatal SAB was specifically associated with older age and multi-morbidity. Metastatic SAB was specifically associated with community acquisition, persistent fever, persistent bacteremia, and recurrence. Endocarditis was over-represented in the fatal/metastatic SAB overlap group, which shared patient characteristics with fatal SAB. In contrast to other (predominantly musculoskeletal) metastatic complications, endocarditis was associated with increased mortality, with death occurring in older multi-morbid patients later after SAB onset. CONCLUSIONS: Patients with SAB experience distinct clinical endpoints: (i) early death, associated with multi-morbidity and age; (ii) metastatic (predominantly musculoskeletal) SAB; (iii) endocarditis, associated with late death occurring in older people with multi-morbidity, and (iv) bacteraemia without complications. These distinctions could be important for selecting appropriate outcomes in clinical trials: different interventions might be required to reduce mortality versus improve clinical response in patients with metastatic SAB.
引用
- Russell CD, Berry K, Cooper G, et al. Distinct Clinical Endpoints of Staphylococcus aureus Bacteraemia Complicate Assessment of Outcome. Clin Infect Dis. 2024. PMID: 38767234. doi:10.1093/cid/ciae281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。